Home/Pipeline/SCO-940

SCO-940

Obesity

PreclinicalPartnered

Key Facts

Indication

Obesity

Phase

Preclinical

Status

Partnered

Company

SCOHIA PHARMA

About SCOHIA PHARMA

A Japanese bioventure developing innovative small molecule drugs for metabolic, cardiovascular, and renal diseases through a diversified pipeline and strategic collaborations.

View full company profile

Therapeutic Areas

Metabolic Cardiovascular Renal Endocrine Rare Diseases

Other Obesity Drugs

Drug	Company	Phase	Status
LET003	Harbour BioMed	Discovery	Active (Global)
LET001	Harbour BioMed	Discovery	Active (Global)
RGT-075	Regor Therapeutics	Phase 2b	Active
Anti‑Obesity Oral Drug	Premas Biotech	Phase 1	Active
Obesity Target Discovery Collaboration	Fauna Bio	Target Discovery/Preclinical	Active
GLP-1 variants	Heligenics	Discovery	Active
MYO Platform (Metabolic Disease)	Renbio	Pre-clinical	Active
Obesity Clinical Trials	IMA Clinical Research	Not Applicable (Service)	Active
KAYO-2000	KayoThera	Preclinical	Active
MVD-1 (SANA)	Eolo Pharma	Phase 1	Active
GIP-neutralizing antibody	Helicore Biopharma	Pre-clinical	Active
Antral Gastroplasty / Endoscopic Sleeve	Endo-TAGSS	Pre-clinical	Active